GLP-1 medications and fatty liver disease: ESSENCE trial findings

Metabolic-associated fatty liver disease affects roughly 30% of the global adult population and is particularly common in people with obesity and type 2 diabetes. When the disease progresses to MASH - metabolic dysfunction-associated steatohepatitis - the risk of cirrhosis, liver transplantation, and liver-related death increases substantially. In August 2025, semaglutide became the first GLP-1 medication to receive FDA approval specifically for MASH, based on the ESSENCE trial. The trial showed 62.9% of semaglutide-treated patients achieved MASH resolution without fibrosis worsening, versus 34.3% with placebo.

TL;DR

The ESSENCE trial tested semaglutide in 965 adults with MASH and fibrosis. Primary endpoint: 62.9% achieved MASH resolution without fibrosis worsening versus 34.3% placebo. Semaglutide is now FDA-approved for MASH treatment. The mechanism involves weight loss, improved insulin sensitivity, and anti-inflammatory effects on the liver.

What ESSENCE tested and found

The ESSENCE trial enrolled 965 adults with biopsy-confirmed MASH and liver fibrosis (stages F2-F3). Participants were randomised to semaglutide or placebo over approximately 72 weeks, with liver biopsy performed at baseline and end of study.

Primary endpoint: MASH resolution without worsening of fibrosis

• Semaglutide: 62.9% achieved the primary endpoint
• Placebo: 34.3% achieved it

Secondary endpoints showed semaglutide improved liver stiffness, reduced hepatic fat content, and produced average weight loss of 13.8% at maximum dose.

Why this approval matters

For decades, the only treatment for MASH was lifestyle modification. Semaglutide offers a proven pharmacological bridge, particularly for the high-risk population with established fibrosis at imminent danger of progression to cirrhosis.

The mechanism is multifaceted: weight loss reduces hepatic triglyceride accumulation, improved insulin sensitivity reduces the driving force for fat storage, and anti-inflammatory effects reduce hepatocyte injury and fibrosis progression.

Supporting liver health on GLP-1 medications

The same nutrients that support overall metabolic health support liver health: magnesium (cofactor in fatty acid oxidation), B vitamins (required for hepatocyte function), and antioxidant vitamins (protect against oxidative stress-driven damage). All are commonly depleted in GLP-1 users. GLP-1 Shield is formulated around these nutrient gaps.

Frequently asked questions

Does Ozempic treat fatty liver disease?

Semaglutide is now FDA-approved specifically for MASH (metabolic dysfunction-associated steatohepatitis) with fibrosis. The ESSENCE trial showed 62.9% of patients achieved MASH resolution on semaglutide versus 34.3% on placebo. This is approval for treatment of established MASH with fibrosis, not for fatty liver prevention.

How do I know if I have MASH versus just fatty liver?

MASLD (fatty liver) is diagnosed by imaging. MASH (inflammatory fatty liver) requires liver biopsy to confirm inflammation and cellular damage. Many people with obesity or diabetes have MASLD without knowing it.

Should I get a liver biopsy if I am overweight or diabetic?

Routine screening is not current standard practice. However, if you have imaging suggesting advanced MASLD, liver assessment by a hepatologist is appropriate.